Author: CSTONE PHARMACEUTICALS

Posted Date:

May 31, 2026

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

CSTONE PHARMACEUTICALS

May 31, 2026
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

CSTONE PHARMACEUTICALS

April 19, 2026
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

CSTONE PHARMACEUTICALS

March 26, 2026
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

CSTONE PHARMACEUTICALS

March 26, 2026
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC

CSTONE PHARMACEUTICALS

February 22, 2026
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

CSTONE PHARMACEUTICALS

February 15, 2026